Content continues after advertisement

Research Note: Treatment Options for Canine Hypercortisolism

Sign in to Print/View PDF

Because of the potential serious side effects associated with mitotane use, trilostane has largely replaced mitotane for treatment of spontaneous canine hypercortisolism. However, trilostane does not affect growth or metastases of cortisol-secreting adrenocortical tumors, which account for 15% to 20% of cases. New targeted treatment options are therefore desirable. This study first showed that a canine primary adrenocortical cell culture can be a useful in vitro system for testing new treatment options. Based on the importance of steroidogenic factor-1 (SF-1) on adrenal steroidogenesis, the study then examined the effect of 3 SF-1 inverse agonists on cortisol production using this in vitro culture system. One of the tested compounds, #31, was shown to be an effective inhibitor of cortisol production and SF-1 target gene expression in non-ACTH–stimulated and ACTH-stimulated normal adrenocortical cells, warranting further study of its use as a potential treatment option in canine hypercortisolism.

Source

For global readers, a calculator to convert laboratory values, dosages, and other measurements to SI units can be found here.

Material from Clinician's Brief may not be reproduced, distributed, or used in whole or in part without prior permission of Educational Concepts, LLC. For questions or inquiries please contact us.

Continuing Education

Welcome to your new CE platform

Get started here.

With RACE-approved courses for the brief, relevant Clinician’s Brief articles you love, we’re your home for online CE.
Earn Hours
39.5
Earn up to 39.5 hours of RACE-approved CE with Clinician’s Brief content.
Clinician's Brief provides relevant diagnostic and treatment information for small animal practitioners. It has been ranked the #1 most essential publication by small animal veterinarians for 9 years.*

*2007-2017 PERQ and Essential Media Studies

© 2018 Educational Concepts, L.L.C. dba Brief Media ™ All Rights Reserved. Privacy Policy (Updated 05/08/2018) Terms of Use (Updated 05/08/2018)